CELGENE CORPORATION for CELGENE CORPORATION
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Corporate Tax Reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALAN EISENBERG | — |
| PATRICK GLIHA | — |
| MATTHEW SCHUMAKER | — |
Copyright/Patent/Trademark CPT
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALAN EISENBERG | — |
| PATRICK GLIHA | — |
| MATTHEW SCHUMAKER | — |
Health Issues HCR
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALAN EISENBERG | — |
| PATRICK GLIHA | — |
| MATTHEW SCHUMAKER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.